We aimed to assess the efficacy , safety , and effective treatment duration of grazoprevir ( an HCV NS3/4A protease inhibitor ) combined with elbasvir ( an HCV NS5A inhibitor ) with or without ribavirin in patients with HCV genotype 1 infection with baseline characteristics of poor response .